関 朋子

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Network Meta-Analysis 54%
3. human ERBB2 protein 47%
4. eribulin 44%
5. Breast 33%
6. Neoadjuvant Therapy 31%
7. Propensity Score 29%
8. Drug Therapy 26%
9. Ductal Carcinoma 20%
10. Simple Mastectomy 19%
11. Deep Learning 18%
12. Lobular Carcinoma 18%
13. Selective Estrogen Receptor Modulators 18%
14. Artificial Intelligence 18%
15. Anthracyclines 17%
16. Safety 17%
17. Palonosetron 16%
18. Aromatase Inhibitors 16%
19. Nipples 16%
20. Antiemetics 16%
21. Adjuvant Chemotherapy 16%
22. Homeobox Genes 15%
23. Neoplasms 15%
24. Mastectomy 15%
25. Patient Reported Outcome Measures 14%
26. Cancer Survivors 14%
27. NF-kappa B 14%
28. Mutation Rate 14%
29. Feasibility Studies 14%
30. Lymph Node Excision 13%
31. Therapeutics 12%
32. Dexamethasone 12%
33. Nausea 12%
34. Vomiting 11%
35. Dissection 11%
36. Olanzapine 11%
37. Epidermal Growth Factor 11%
38. Lapatinib 10%
39. Trastuzumab 10%
40. Immunoglobulin G 10%
41. Data Analysis 10%
42. Systematic Reviews 10%
43. Hormones 9%
44. Immunoglobulin G4-Related Disease 9%
45. pertuzumab 9%
46. Magnetic Resonance Imaging 9%
47. Estrogen Receptors 8%
48. Messenger RNA 7%
49. Mutation 7%
50. Needle Biopsy 7%